Business
Natera provides genetic testing using molecular and bioinformatics technology.
Natera grew revenue, reported a net loss, generated positive free cash flow at a -13.4% operating margin. Revenue grew rapidly and free cash flow turned positive, but the company still reported a loss and negative operating margin.
The read at a glance✓ Audited against SEC data
- Growth — Revenue grew 35.9%OK
- Profitability — The net loss widened from $190.426M to $208.16MWatch
- Cash flow — Free cash flow grew 57.6% to $109.113M from $69.241MOK
- Margins — Operating margin contracted 34 bps to -13.44%Watch
- Accounting — Revenue grew rapidly and free cash flow turned positive, but the company still reported a loss and negative operating marginWatch
- Insiders — 0 purchases and 157 salesWatch
Where the revenue comes from
Fiscal 2025, as Natera, Inc. reports it. History and quarterly detail are in the app.
- Product$2.3B
- Licensing And Other$10.3M
Leadership changes
From Natera, Inc.'s own filings, the day they're filed.
- Thomas Lynch · director · appointmenteff. 2026-06-02
- Eric Rubin · director · appointmenteff. 2026-03-26
Latest filings
- 10-Q · Quarterly report2026-08-07
- 8-K · Company announcement2026-08-06
- 8-K · Company announcement2026-07-06
- 8-K · Company announcement2026-06-16
- 8-K · Company announcement2026-06-05
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about Natera, Inc., every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.